Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

pegaptanib (Rx)Brand and Other Names:Macugen

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

intravitreous injection

  • 0.3mg/90mcL (prefilled syringe)
more...

Neovascular (Wet) Age-Related Macular Degeneration

0.3 mg intravitreous q6Weeks

Indication not applicable to children

Next

Adverse Effects

>10%

Anterior chamber inflammation

Blurred vision

Cataract

Conjunctival hemorrhage

Corneal edema

Eye discharge, irritation, pain

Hypertension

Inceased IOP

Ocular discomfort

Punctate keratitis

Reduced visual acuity

Visual disturbance

Vitreous floaters

Vitreous opacities

1-10%

Allergic conjunctivitis

Blepharitis

Conjunctival edema

Conjuctivitis

Corneal abrasion, corneal deposits, corneal epithelial d/o

Contact dermatitis

Endophthalmitis

Eye inflammation/swelling, eyelid irritation

Mydriasis

Periorbital hematoma

Photopsia

Retinal edema

Vitreous d/o, vitreous hemorrhage

Arthritis

Bone spur

Bronchitis

Carotid artery occlusion

Chest pain, contusion

CVA/TIA

Dizziness

Headache

Hearing loss

Meibomianitis

Pleural effusion

Urinary retention

UTI

Diabetes mellitus

Diarrhea

Dyspepsia

Nausea

Vomiting

<1%

Iatrogenic traumatic cataract

Retinal detachment

Angioedema hypersensitivity

Previous
Next

Warnings

Contraindications

Hypersensitivity

Ocular/periocular infections

Cautions

Use proper aseptic techniques to minimize risk of endophthalmitis

Risk of increased IOP; monitor IOP and perfusion of the optic nerve

In clinical studies, less effective in the second year than during the first

Efficacy decreased at doses >1 mg

Thromboembolic events reported following intravitreal administration of other VEGF inhibitors

Safety and efficacy of concurrent administration on both eyes not studied

Previous
Next

Pregnancy & Lactation

Pregnancy Category: B

No adequate human data; in mice, produced no maternal toxicity and no evidence of teratogenicity or fetal mortality at IV doses up to 40 mg/kg/day (about 7,000 times the recommended human monocular ophthalmic dose of 0.3 mg/eye)

Lactation: Ecretion in breast milk unknown; use caution

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next

Pharmacology

Mechanism of Action

Aptamer that binds to and inhibits binding of the angiogenic cytokine VEGF to the receptor, which in turn suppresses neovascularization and slows vision loss

Metabolism

Endo- and exonucleases (based on preclinical data)

Elimination

Excretion: Primarily urine

Half-life: 6-14 days

Previous
Next

Images

Previous
Next

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Add or Remove Plans
Plans for
Select State:
Non-Medicare PlansMedicare Plans

Select a box to add or remove a plan.

Select a class to view formulary status for similar drugs

Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.